Health
MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials – News-Medical.Net
A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic….
The modified vaccina virus Ankara (MVA) is an attenuated vaccinia virus that has been used as a vector in the already approved Adenovirus-MVA-based Ebola vaccine. A new preprint appearing on the bioRxiv* server reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that is causing the current coronavirus disease 2019 (COVID-19) pandemic. The MVA provides a vector platform for the rapid production…
-
Noosa News23 hours agoRiverfire 2025: What time the fireworks start, where to watch and how to get home
-
Business18 hours agoShould you avoid Nvidia stock?
-
Noosa News23 hours agoQld prepares for hot, windy weekend with high fire danger at Birdsville Races
-
Noosa News21 hours agoBrisbane news LIVE updates: Tributes for young Brisbane skier Sean Forrest who died at Thredbo | Reece Walsh delivers Broncos’ warning in triumph over Storm